Relay Therapeutics AnalystMaintains Buy
This is a news story, published by Yahoo Finance, that relates primarily to Jason Gerberry news.
Jason Gerberry news
For more Jason Gerberry news, you can click here:
more Jason Gerberry newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Relay Therapeutics. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest selective inhibitor news, stage precision medicine company news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
PI3KαInsider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
•Health
Health
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT

80% Informative
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on June 3 and set a price target of $ 17.00 .
RLY-2608 is the first known investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3K.
VR Score
78
Informative language
77
Neutral language
31
Article tone
formal
Language
English
Language complexity
65
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
4
Source diversity
1
Affiliate links
no affiliate links